Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes | Synapse
March 3, 2026Open Access
Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes
Key Points
Fertility restoration is observed in patients undergoing combined GLP-1RA and SGLT2i therapy, offering new hope for those affected.
This therapy is particularly effective among individuals with obesity and polycystic ovary syndrome, highlighting its unique role.
Observational analysis evaluates the effects on fertility, with particular attention to management of type 2 diabetes.
These findings suggest a need for broader acceptance of combined therapies, especially in populations at risk for diabetes and reproductive issues.